1-Methylnicotinamide (1-MNA) inhibits the activation of the NLRP3 inflammasome in human macrophages
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110445 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Karolina Sidor und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Immunology and Experimental Intensive Care, Centre of Postgraduate Medical Education, Warsaw, Poland. Hauptthemen laut MEDLINE: Inflammasomes, NLR Family, Pyrin Domain-Containing 3 Protein. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki.
Abstract (Originalsprache)
The NLRP3 inflammasome is among the most potent intracellular sensors of danger and disturbances of cellular homeostasis that can lead to the release of IL-1β and cell death, or pyroptosis. Despite its protective role, this mechanism is involved in the pathogenesis of numerous inflammatory diseases; therefore, it is seen as a potential therapeutic target. 1-methylnicotinamide (1-MNA) is a direct metabolite of nicotinamide and was previously shown to display several immunomodulatory properties, including a reduction in the reactive oxygen species (ROS). Here, we investigated whether 1-MNA could influence the activation of the NLRP3 inflammasome in human macrophages. In differentiated human macrophages we observed that 1-MNA specifically reduced the activation of the NLRP3 inflammasome. This effect was related to the scavenging of ROS, as exogenous H2O2 was able to restore NLRP3 activation. Additionally, 1-MNA increased the mitochondrial membrane potential, indicating that it did not inhibit oxidative phosphorylation. Moreover, at high but not low concentrations, 1-MNA decreased NF-κB activation and the level of pro-IL-1β. Interestingly, 1-MNA did not reduce the secretion of IL-6 upon endotoxin stimulation, confirming that its primary immunomodulatory effect on human macrophages is dependent on the NLRP3 inflammasome. Taken together, we have shown for the first time that 1-MNA reduced the activation of the NLRP3 inflammasome in human macrophages via an ROS-dependent pathway. Our results indicate a novel potential use of 1-MNA in NLRP3-related disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Immunology and Experimental Intensive Care, Centre of Postgraduate Medical Education, Warsaw, Poland.
- Department of Translational Immunology and Experimental Intensive Care, Centre of Postgraduate Medical Education, Warsaw, Poland. Electronic address: tskirecki@cmkp.edu.pl.
Förderung
- Narodowe Centrum Nauki
Zitieren
APA
Sidor, K., Jeznach, A., Hoser, G., & Skirecki, T. (2023). 1-Methylnicotinamide (1-MNA) inhibits the activation of the NLRP3 inflammasome in human macrophages. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110445
Vancouver
Sidor K, Jeznach A, Hoser G, Skirecki T. 1-Methylnicotinamide (1-MNA) inhibits the activation of the NLRP3 inflammasome in human macrophages. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110445
BibTeX
@article{Sidor2023,
author = {Sidor, Karolina and Jeznach, Aldona and Hoser, Grażyna and Skirecki, Tomasz},
title = {1-Methylnicotinamide (1-MNA) inhibits the activation of the NLRP3 inflammasome in human macrophages},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110445}
}
EUVIMED